艾伯维公司旗下爱力根美学部门近日宣布，其新型神经调节剂Boey®（Trenibotulinumtoxine）已获得欧洲药品管理局人用医药产品委员会的积极评价。该意见支持Boey®用于暂时改善成人中重度眉间纹。
这一积极意见是Boey®在欧盟市场获批上市前的关键步骤。若最终获得批准，该产品将为寻求改善眉间纹外观的成年人提供一种新的治疗选择。爱力根美学在神经调节剂领域拥有深厚的研发经验，此次进展进一步巩固了其在医学美学领域的创新地位。
眉间纹是面部常见的动态皱纹，由反复的肌肉收缩形成。Boey®作为一种含有Trenibotulinumtoxine成分的产品，其作用机制旨在暂时性地减弱导致皱纹形成的特定肌肉活动。公司表示，将继续与监管机构合作，推动该产品后续的审批进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.